 Kevin Lillehei
Concepts (613)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Neoplasms | 29 | 2025 | 194 | 3.570 |
Why?
| | Adenoma | 23 | 2025 | 217 | 3.170 |
Why?
| | Brain Neoplasms | 48 | 2023 | 1282 | 2.970 |
Why?
| | Neurosurgical Procedures | 11 | 2025 | 199 | 2.050 |
Why?
| | Meningioma | 12 | 2022 | 89 | 1.950 |
Why?
| | Pituitary Gland | 11 | 2020 | 151 | 1.700 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 13 | 1.600 |
Why?
| | Glioblastoma | 18 | 2023 | 344 | 1.570 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 1075 | 1.360 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 97 | 1.300 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 19 | 1.090 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 169 | 0.920 |
Why?
| | Glioma | 15 | 2020 | 418 | 0.890 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 136 | 0.850 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.850 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.830 |
Why?
| | Cysts | 3 | 2020 | 113 | 0.750 |
Why?
| | Carmustine | 3 | 2017 | 51 | 0.710 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 717 | 0.700 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 11 | 0.690 |
Why?
| | Cancer Vaccines | 5 | 2018 | 165 | 0.680 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 98 | 0.670 |
Why?
| | Hypopituitarism | 1 | 2020 | 16 | 0.650 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 100 | 0.630 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 217 | 0.590 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 133 | 0.580 |
Why?
| | Polyesters | 2 | 2017 | 78 | 0.560 |
Why?
| | Bleomycin | 1 | 2019 | 239 | 0.550 |
Why?
| | Decanoic Acids | 1 | 2017 | 12 | 0.550 |
Why?
| | Immunotherapy | 4 | 2006 | 641 | 0.550 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3734 | 0.530 |
Why?
| | Adult | 72 | 2025 | 39319 | 0.510 |
Why?
| | Orbital Diseases | 1 | 2016 | 32 | 0.500 |
Why?
| | Middle Aged | 73 | 2025 | 34658 | 0.500 |
Why?
| | Aged | 54 | 2025 | 24836 | 0.470 |
Why?
| | Humans | 126 | 2025 | 141284 | 0.440 |
Why?
| | Male | 86 | 2025 | 70140 | 0.420 |
Why?
| | Female | 83 | 2025 | 75814 | 0.390 |
Why?
| | Brachial Plexus | 3 | 2007 | 34 | 0.390 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2162 | 0.380 |
Why?
| | Retrospective Studies | 28 | 2025 | 16447 | 0.370 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1250 | 0.370 |
Why?
| | Dacarbazine | 7 | 2015 | 95 | 0.370 |
Why?
| | Skull Neoplasms | 4 | 2012 | 21 | 0.360 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 232 | 0.360 |
Why?
| | Cisplatin | 3 | 1998 | 328 | 0.350 |
Why?
| | Craniopharyngioma | 3 | 2020 | 78 | 0.340 |
Why?
| | Extracellular Vesicles | 2 | 2024 | 153 | 0.340 |
Why?
| | Cautery | 1 | 2010 | 4 | 0.330 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 358 | 0.330 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 70 | 0.330 |
Why?
| | Sella Turcica | 5 | 2018 | 17 | 0.320 |
Why?
| | Monosomy | 1 | 2010 | 12 | 0.320 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 12 | 0.320 |
Why?
| | Epithelioid Cells | 1 | 2010 | 9 | 0.320 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 45 | 0.320 |
Why?
| | Neurosurgery | 2 | 2021 | 42 | 0.320 |
Why?
| | Astrocytoma | 5 | 2014 | 130 | 0.320 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1243 | 0.310 |
Why?
| | Hemangioma | 1 | 2009 | 45 | 0.300 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 125 | 0.300 |
Why?
| | Cadherins | 2 | 2024 | 200 | 0.290 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 310 | 0.290 |
Why?
| | Membrane Proteins | 2 | 2017 | 1144 | 0.280 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 100 | 0.280 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 29 | 0.270 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 396 | 0.270 |
Why?
| | Young Adult | 16 | 2025 | 13727 | 0.270 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.270 |
Why?
| | Tumor Cells, Cultured | 8 | 2017 | 959 | 0.270 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1724 | 0.260 |
Why?
| | Prolactinoma | 3 | 2019 | 14 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 1439 | 0.250 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 36 | 0.240 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 19 | 0.240 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1491 | 0.240 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 110 | 0.240 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 12 | 0.240 |
Why?
| | Gonadotrophs | 5 | 2015 | 22 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 68 | 0.240 |
Why?
| | Ethanol | 1 | 2010 | 627 | 0.240 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 265 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 757 | 0.220 |
Why?
| | Interleukin-2 | 6 | 1997 | 448 | 0.220 |
Why?
| | Chordoma | 1 | 2024 | 17 | 0.220 |
Why?
| | Neoplasms | 5 | 2013 | 2731 | 0.220 |
Why?
| | Hemangioblastoma | 1 | 2004 | 3 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2020 | 11216 | 0.210 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1483 | 0.210 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 98 | 0.210 |
Why?
| | Adolescent | 20 | 2020 | 22116 | 0.210 |
Why?
| | Osteoblasts | 1 | 2024 | 136 | 0.210 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 147 | 0.210 |
Why?
| | Postoperative Complications | 8 | 2018 | 2831 | 0.200 |
Why?
| | Cell Movement | 2 | 2024 | 962 | 0.200 |
Why?
| | Neurologic Examination | 3 | 2019 | 127 | 0.200 |
Why?
| | Cauda Equina | 2 | 2004 | 6 | 0.200 |
Why?
| | Transcription Factors | 2 | 2010 | 1706 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 8 | 0.200 |
Why?
| | Drug Implants | 3 | 2017 | 82 | 0.200 |
Why?
| | Postoperative Period | 3 | 2020 | 359 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 213 | 0.190 |
Why?
| | Motor Cortex | 1 | 2003 | 63 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 110 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 173 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 528 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1791 | 0.180 |
Why?
| | Pituitary Diseases | 3 | 2017 | 20 | 0.180 |
Why?
| | Pineal Gland | 1 | 2021 | 15 | 0.180 |
Why?
| | Pinealoma | 1 | 2021 | 9 | 0.180 |
Why?
| | Fistula | 1 | 2022 | 48 | 0.180 |
Why?
| | Aspergillus | 2 | 2013 | 19 | 0.180 |
Why?
| | Prognosis | 10 | 2021 | 4080 | 0.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 225 | 0.170 |
Why?
| | Frontal Bone | 2 | 2015 | 20 | 0.170 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 59 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 890 | 0.170 |
Why?
| | Follow-Up Studies | 8 | 2017 | 5222 | 0.170 |
Why?
| | Neuropathology | 1 | 2020 | 3 | 0.170 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 111 | 0.170 |
Why?
| | Telepathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 61 | 0.170 |
Why?
| | Prospective Studies | 11 | 2023 | 7805 | 0.160 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.160 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 2 | 0.160 |
Why?
| | Fluorescein | 1 | 2020 | 23 | 0.160 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 630 | 0.160 |
Why?
| | Salivary Glands | 1 | 2020 | 36 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 711 | 0.160 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 40 | 0.160 |
Why?
| | Survival Analysis | 7 | 2018 | 1322 | 0.160 |
Why?
| | Nose Neoplasms | 1 | 2000 | 25 | 0.160 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 29 | 0.160 |
Why?
| | Transcriptome | 3 | 2024 | 1007 | 0.160 |
Why?
| | Radiosurgery | 3 | 2010 | 389 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2765 | 0.150 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 84 | 0.150 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2554 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2017 | 311 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Dendritic Cells | 2 | 2023 | 487 | 0.150 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 14 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 15 | 0.150 |
Why?
| | Oligodendroglioma | 2 | 2014 | 15 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 383 | 0.150 |
Why?
| | International Educational Exchange | 1 | 2018 | 11 | 0.150 |
Why?
| | Endocrine Glands | 1 | 1998 | 15 | 0.150 |
Why?
| | ErbB Receptors | 4 | 2006 | 612 | 0.140 |
Why?
| | Aged, 80 and over | 12 | 2020 | 7948 | 0.140 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 11 | 0.140 |
Why?
| | Survival Rate | 6 | 2015 | 1979 | 0.140 |
Why?
| | Antioxidants | 2 | 2000 | 593 | 0.140 |
Why?
| | Stroke | 2 | 2021 | 1199 | 0.140 |
Why?
| | Time Factors | 10 | 2011 | 6951 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 41 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2004 | 897 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 99 | 0.140 |
Why?
| | Remission Induction | 1 | 2018 | 306 | 0.140 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 28 | 0.140 |
Why?
| | Mutation | 3 | 2014 | 4006 | 0.130 |
Why?
| | Quinazolines | 2 | 2010 | 260 | 0.130 |
Why?
| | Rats | 8 | 2006 | 5556 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 144 | 0.130 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1761 | 0.130 |
Why?
| | Xanthomatosis | 1 | 2017 | 8 | 0.130 |
Why?
| | Desmosomes | 1 | 2017 | 21 | 0.130 |
Why?
| | Third Ventricle | 1 | 2017 | 15 | 0.130 |
Why?
| | Reoperation | 5 | 2020 | 599 | 0.130 |
Why?
| | Exophthalmos | 1 | 2016 | 17 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 370 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2015 | 2502 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2079 | 0.120 |
Why?
| | Brain Injuries | 1 | 2021 | 503 | 0.120 |
Why?
| | Progesterone | 1 | 2017 | 258 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1125 | 0.120 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 25 | 0.120 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.120 |
Why?
| | Tibial Nerve | 1 | 1995 | 9 | 0.120 |
Why?
| | Occipital Lobe | 2 | 2006 | 26 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 75 | 0.120 |
Why?
| | Glycoproteins | 3 | 2012 | 354 | 0.120 |
Why?
| | Genes, p53 | 2 | 2011 | 68 | 0.120 |
Why?
| | Olfactory Pathways | 1 | 2015 | 38 | 0.110 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 320 | 0.110 |
Why?
| | Accidents, Aviation | 1 | 1994 | 5 | 0.110 |
Why?
| | Proteome | 2 | 2024 | 483 | 0.110 |
Why?
| | Karyotyping | 3 | 2008 | 104 | 0.110 |
Why?
| | Orbit | 1 | 2015 | 70 | 0.110 |
Why?
| | Molecular Chaperones | 2 | 2013 | 198 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 431 | 0.110 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 510 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 1995 | 84 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 41 | 0.110 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 41 | 0.110 |
Why?
| | Ganglioglioma | 1 | 2014 | 35 | 0.110 |
Why?
| | Human Growth Hormone | 1 | 2014 | 46 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 26 | 0.100 |
Why?
| | Ganglioneuroma | 1 | 2013 | 1 | 0.100 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 3 | 0.100 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 117 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2008 | 373 | 0.100 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 6 | 0.100 |
Why?
| | Seizures | 1 | 2017 | 441 | 0.100 |
Why?
| | Aspergillosis | 1 | 2013 | 22 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.100 |
Why?
| | Child | 9 | 2022 | 22390 | 0.100 |
Why?
| | Telomerase | 3 | 2003 | 249 | 0.100 |
Why?
| | Joint Dislocations | 1 | 1993 | 55 | 0.100 |
Why?
| | Cell Division | 5 | 2012 | 792 | 0.100 |
Why?
| | Spinal Injuries | 1 | 1993 | 58 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 251 | 0.100 |
Why?
| | Patient Readmission | 1 | 2018 | 698 | 0.100 |
Why?
| | Dog Diseases | 1 | 2013 | 67 | 0.090 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 85 | 0.090 |
Why?
| | Muscles | 1 | 1993 | 331 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 120 | 0.090 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1050 | 0.090 |
Why?
| | Craniotomy | 3 | 2015 | 78 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 25 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 68 | 0.090 |
Why?
| | Spine | 1 | 1993 | 179 | 0.090 |
Why?
| | Curriculum | 1 | 2018 | 1035 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 78 | 0.090 |
Why?
| | Skull | 2 | 2007 | 146 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1105 | 0.090 |
Why?
| | Mitotic Index | 2 | 2011 | 25 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3502 | 0.090 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 8 | 0.090 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 120 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2904 | 0.080 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.080 |
Why?
| | Claudins | 1 | 2010 | 24 | 0.080 |
Why?
| | Tumor Burden | 4 | 2012 | 314 | 0.080 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 32 | 0.080 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 12 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 57 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2003 | 266 | 0.080 |
Why?
| | Animals | 14 | 2013 | 37328 | 0.080 |
Why?
| | Lymphoma | 2 | 2008 | 228 | 0.080 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 325 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2205 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 217 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.070 |
Why?
| | Cell Survival | 5 | 2015 | 1123 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2008 | 336 | 0.070 |
Why?
| | Arm Injuries | 1 | 1988 | 23 | 0.070 |
Why?
| | Prolactin | 3 | 2019 | 92 | 0.070 |
Why?
| | Dogs | 2 | 2013 | 423 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 221 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 628 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 2 | 2025 | 27 | 0.070 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 12 | 0.070 |
Why?
| | Internship and Residency | 1 | 2018 | 1230 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 771 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 280 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 71 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 93 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 9 | 0.070 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 18 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 100 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 13 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 346 | 0.070 |
Why?
| | Hematoma | 2 | 1985 | 55 | 0.070 |
Why?
| | Scalp | 1 | 2007 | 35 | 0.060 |
Why?
| | Adenoviridae | 1 | 2008 | 199 | 0.060 |
Why?
| | Blood Vessels | 1 | 1988 | 173 | 0.060 |
Why?
| | Radiography | 3 | 2013 | 845 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 43 | 0.060 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1397 | 0.060 |
Why?
| | Enophthalmos | 1 | 2006 | 2 | 0.060 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 10 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 468 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 14 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 1994 | 917 | 0.060 |
Why?
| | Dexamethasone | 4 | 2012 | 375 | 0.060 |
Why?
| | Blepharoptosis | 1 | 2006 | 12 | 0.060 |
Why?
| | Epidermal Cyst | 1 | 2006 | 12 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 153 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 164 | 0.060 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 80 | 0.060 |
Why?
| | Child, Preschool | 5 | 2017 | 11511 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2006 | 59 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 53 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 63 | 0.060 |
Why?
| | Teratoma | 1 | 2007 | 121 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 465 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 36 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 96 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 130 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 315 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1468 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 65 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 51 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 204 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 218 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 309 | 0.060 |
Why?
| | Exons | 1 | 2006 | 352 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 131 | 0.060 |
Why?
| | Antigens, CD | 2 | 2024 | 537 | 0.060 |
Why?
| | Cushing Syndrome | 1 | 2004 | 10 | 0.060 |
Why?
| | Calcitonin | 1 | 2004 | 29 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2006 | 4414 | 0.050 |
Why?
| | Databases, Factual | 1 | 2010 | 1449 | 0.050 |
Why?
| | Medulloblastoma | 1 | 2007 | 218 | 0.050 |
Why?
| | Myelography | 2 | 2022 | 37 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2069 | 0.050 |
Why?
| | Bevacizumab | 2 | 2015 | 135 | 0.050 |
Why?
| | Subarachnoid Space | 1 | 2004 | 9 | 0.050 |
Why?
| | S100 Proteins | 2 | 1995 | 36 | 0.050 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.050 |
Why?
| | United States | 3 | 2017 | 15298 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 983 | 0.050 |
Why?
| | Brain | 6 | 2017 | 2857 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 14 | 0.050 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 19 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 204 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 375 | 0.050 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 175 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1136 | 0.050 |
Why?
| | Proteomics | 2 | 2024 | 1137 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 494 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 605 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 191 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 34 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 3295 | 0.050 |
Why?
| | Quality of Life | 2 | 2013 | 3024 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2809 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 435 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 510 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2808 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 309 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 26 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 198 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 478 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3577 | 0.040 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 159 | 0.040 |
Why?
| | Thyrotropin | 5 | 1999 | 116 | 0.040 |
Why?
| | Spinal Cord | 1 | 2004 | 374 | 0.040 |
Why?
| | Public Opinion | 1 | 2021 | 60 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 65 | 0.040 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 65 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2003 | 840 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 105 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 9 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 170 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 43 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 110 | 0.040 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 855 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 117 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 16 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 321 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 42 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 851 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 17 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 457 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1108 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 851 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2487 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 361 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 35 | 0.040 |
Why?
| | Infant | 2 | 2008 | 9820 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 405 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1073 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 22 | 0.030 |
Why?
| | Capacity Building | 1 | 2018 | 59 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 90 | 0.030 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 29 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2018 | 77 | 0.030 |
Why?
| | Meningomyelocele | 1 | 1998 | 61 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 181 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 334 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 367 | 0.030 |
Why?
| | Cell Line | 3 | 2012 | 2863 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 56 | 0.030 |
Why?
| | Preoperative Care | 2 | 2003 | 372 | 0.030 |
Why?
| | Brain Diseases | 2 | 1998 | 150 | 0.030 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 449 | 0.030 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 11 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2000 | 784 | 0.030 |
Why?
| | Hydrocephalus | 2 | 2017 | 110 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 24 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2017 | 24 | 0.030 |
Why?
| | Premenopause | 1 | 2017 | 120 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 40 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 206 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 643 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 115 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 97 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 91 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 87 | 0.030 |
Why?
| | RNA, Messenger | 5 | 2011 | 2815 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 280 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 520 | 0.030 |
Why?
| | Developing Countries | 1 | 2018 | 308 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 325 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 175 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 176 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 147 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 327 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 943 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1336 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 5116 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 2 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 329 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 303 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 290 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 663 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 222 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1440 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4149 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 57 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 34 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 32 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 20 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 49 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 58 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 22 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 61 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 102 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4599 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 46 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 116 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1362 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 73 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1090 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 278 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 178 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 232 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 768 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 181 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 1009 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 272 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 219 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5809 | 0.030 |
Why?
| | Paresis | 2 | 2007 | 31 | 0.030 |
Why?
| | Nervous System | 1 | 1993 | 69 | 0.020 |
Why?
| | Hypothyroidism | 2 | 1992 | 73 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 287 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 27 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1810 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 438 | 0.020 |
Why?
| | Neuroblastoma | 1 | 1993 | 162 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1807 | 0.020 |
Why?
| | Mice | 4 | 2012 | 17969 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 858 | 0.020 |
Why?
| | Safety | 1 | 1994 | 356 | 0.020 |
Why?
| | Fatal Outcome | 2 | 2007 | 309 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 1993 | 257 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 195 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 52 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 39 | 0.020 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1456 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2047 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1992 | 11 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3345 | 0.020 |
Why?
| | Rhodamine 123 | 2 | 2001 | 8 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 123 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 164 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1312 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 390 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 20 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 449 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 267 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 55 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 37 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 684 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 403 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 512 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 63 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 230 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1764 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 74 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 145 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 130 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 123 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 156 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 393 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 168 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 154 | 0.020 |
Why?
| | Doxorubicin | 2 | 2001 | 369 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 245 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 92 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 765 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 19 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1620 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 35 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 247 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 13 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2055 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 430 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 95 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 106 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 477 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 825 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 855 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 6270 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 34 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3522 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 204 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 463 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 507 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1244 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 255 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 387 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1268 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1059 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 414 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 202 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 577 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 534 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 139 | 0.020 |
Why?
| | Tretinoin | 1 | 2006 | 121 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2008 | 305 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 436 | 0.010 |
Why?
| | Coma | 1 | 1985 | 36 | 0.010 |
Why?
| | Action Potentials | 1 | 1988 | 505 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 374 | 0.010 |
Why?
| | Athletic Injuries | 1 | 1991 | 527 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1985 | 61 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1226 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 146 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1050 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 41 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 592 | 0.010 |
Why?
| | Sound | 1 | 1984 | 54 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 775 | 0.010 |
Why?
| | Blood | 1 | 1984 | 110 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2366 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 49 | 0.010 |
Why?
| | Injections | 1 | 1984 | 191 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 453 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 254 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 70 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 71 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 137 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 55 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 40 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1490 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 15 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 689 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 173 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 187 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4051 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 982 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2146 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2911 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 11 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 31 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 39 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 63 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 78 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 50 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 207 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 72 | 0.010 |
Why?
| | Photography | 1 | 1998 | 114 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 74 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 71 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 149 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 167 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 148 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 333 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 232 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 252 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 514 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5866 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 40 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 233 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 695 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 97 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1973 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 22 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 21 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 46 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 166 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 57 | 0.010 |
Why?
| | Headache | 1 | 1992 | 153 | 0.010 |
Why?
| | Football | 1 | 1991 | 89 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5948 | 0.010 |
Why?
| | Immunochemistry | 1 | 1989 | 12 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 65 | 0.000 |
Why?
| | Hyperthyroidism | 1 | 1989 | 23 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 80 | 0.000 |
Why?
| | Circadian Rhythm | 1 | 1991 | 509 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1113 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1486 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 68 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 32 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 29 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3172 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1996 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2600 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 7035 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|